Lauren E. Cipriano

Lauren E. Cipriano

Auto-generated profile, based on publicly available information

Lauren E. Cipriano

Deputy Editor, Medical Decision Making and MDM Policy & Practice; Ivey Business School and Departments of Medicine and Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in The Lancet Neurology
Verified
Journal Article
Closed access
LSLuciano A Sposato
Luciano A Sposato
LCLauren E Cipriano
Lauren E Cipriano
GSGustavo Saposnik
Gustavo Saposnik
EVEstefanía Ruíz Vargas
Estefanía Ruíz Vargas
PRPatricia M Riccio
Patricia M Riccio
VHVladimir Hachinski
Vladimir Hachinski

1 November 2011 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
PMPamela M. McMahon
Pamela M. McMahon
CKChung Yin Kong
Chung Yin Kong
CBColleen Bouzan
Colleen Bouzan
MWMilton C. Weinstein
Milton C. Weinstein
LCLauren E. Cipriano
Lauren E. Cipriano
GGG. Scott Gazelle
G. Scott Gazelle
Introduction A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level. Methods Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4–30% 1-year abstinence); and combined programs. Results Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation. Conclusions The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.

30 September 2017 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
MAMahmoud Reza Azarpazhooh
Mahmoud Reza Azarpazhooh
AAAbolfazl Avan
Abolfazl Avan
LCLauren E. Cipriano
Lauren E. Cipriano
DMDavid G. Munoz
David G. Munoz
LSLuciano A. Sposato
Luciano A. Sposato
VHVladimir Hachinski
Vladimir Hachinski

21 February 2012 in Annals of Internal Medicine
Verified
Journal Article
Closed access
SLShan Liu
Shan Liu
LCLauren E. Cipriano
Lauren E. Cipriano
MHMark Holodniy
Mark Holodniy
DODouglas K. Owens
Douglas K. Owens
JGJeremy D. Goldhaber-Fiebert
Jeremy D. Goldhaber-Fiebert
Protease inhibitors increase the effectiveness of standard hepatitis C therapy but are costly. Interleukin-28B (IL-28B) genotyping can identify patients most likely to derive benefit from the addit... Background: Chronic hepatitis C virus is difficult to treat and affects approximately 3 million Americans. Protease inhibitors increase the effectiveness of standard therapy, but they are costly. A...

1 February 2017 in Current Opinion in Neurology
Verified
Journal Article
Open access
JCJoshua O. Cerasuolo
Joshua O. Cerasuolo
LCLauren E. Cipriano
Lauren E. Cipriano
LSLuciano A. Sposato
Luciano A. Sposato
Purpose of review: Atrial fibrillation is being increasingly diagnosed after ischemic stroke and transient ischemic attack (TIA). Patient characteristics, frequency and duration of paroxysms, and the risk of recurrent ischemic stroke associated with atrial fibrillation detected after stroke and TIA (AFDAS) may differ from atrial fibrillation already known before stroke occurrence. We aim to summarize major recent advances in the field, in the context of prior evidence, and to identify areas of uncertainty to be addressed in future research. Recent findings: Half of all atrial fibrillations in ischemic stroke and TIA patients are AFDAS, and most of them are asymptomatic. Over 50% of AFDAS paroxysms last less than 30 s. The rapid initiation of cardiac monitoring and its duration are crucial for its timely and effective detection. AFDAS comprises a heterogeneous mix of atrial fibrillation, possibly including cardiogenic and neurogenic types, and a mix of both. Over 25 single markers and at least 10 scores have been proposed as predictors of AFDAS. However, there are considerable inconsistencies across studies. The role of AFDAS burden and its associated risk of stroke recurrence have not yet been investigated. Summary: AFDAS may differ from atrial fibrillation known before stroke in several clinical dimensions, which are important for optimal patient care strategies. Many questions remain unanswered. Neurogenic and cardiogenic AFDAS need to be characterized, as it may be possible to avoid some neurogenic cases by initiating timely preventive treatments. AFDAS burden may differ in ischemic stroke and TIA patients, with distinctive diagnostic and treatment implications. The prognosis of AFDAS and its risk of recurrent stroke are still unknown; therefore, it is uncertain whether AFDAS patients should be treated with oral anticoagulants.

1 January 2011 in Value in Health
Verified
Journal Article
Closed access
LCLauren E. Cipriano
Lauren E. Cipriano
DRDorothy Romanus
Dorothy Romanus
CECraig C. Earle
Craig C. Earle
BNBridget A. Neville
Bridget A. Neville
EHElkan F. Halpern
Elkan F. Halpern
PMPamela M. McMahon
Pamela M. McMahon